In last trading session, Summit Therapeutics Inc (NASDAQ:SMMT) saw 0.7 million shares changing hands with its beta currently measuring -1.02. Company’s recent per share price level of $1.93 trading at $0.07 or 3.76% at ring of the bell on the day assigns it a market valuation of $1.35B. That closing price of SMMT’s stock is at a discount of -199.48% from its 52-week high price of $5.78 and is indicating a premium of 65.8% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.22 million shares which gives us an average trading volume of 973.79K if we extend that period to 3-months.
For Summit Therapeutics Inc (SMMT), analysts’ consensus is at an average recommendation of a Hold while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Upright in the green during last session for gaining 3.76%, in the last five days SMMT remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $1.93 price level, adding 5.85% to its value on the day. Summit Therapeutics Inc’s shares saw a change of -54.59% in year-to-date performance and have moved 1.31% in past 5-day. Summit Therapeutics Inc (NASDAQ:SMMT) showed a performance of 4.89% in past 30-days. Number of shares sold short was 9.48 million shares which calculate 9.92 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 51.75% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $4.00. It follows that stock’s current price would drop -107.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -107.25% for stock’s current value.
Summit Therapeutics Inc (SMMT) estimates and forecasts
This year revenue growth is estimated to fall -92.30% from the last financial year’s standing.
Company posted $4.55 million and $192k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.32% during past 5 years.
Summit Therapeutics Inc is more likely to be releasing its next quarterly report on November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.